AI swarm targets CD276 in the hunt for a lung-cancer drug
A Stanford-led study built a ‘Virtual Biotech’ of up to 37,000 AI agents that analyzed results from more than 55,000 clinical trials and gene-activity data. The system identified CD276 as a promising lung-cancer target and proposed an antibody-drug conjugate strategy, demonstrating how AI could accelerate drug discovery, though the approach has not been experimentally or clinically validated and requires human oversight.